A phase II trial of sitravatinib plus nivolumab after progression on prior immune checkpoint inhibitor (ICI) in patients with metastatic clear cell renal cell carcinoma (ccRCC). Anlotinib combined ...
Investigators delivered updated results from the phase 3 PHILA trial evaluating the pyrotinib or placebo plus trastuzumab and docetaxel in patients with untreated HER2+metastatic breast cancer.
The intricate regulation of receptor tyrosine kinases (RTKs) underpins a vast array of cellular responses that are essential for growth, differentiation and survival. In particular, the interplay ...
In the meta-analysis, the median follow-up ranged from 2 to 14 years and the median OS was between 10.1 and 12.7 months (where reported). Comparing patients with tumors NTRK+ and NTRK–, the pooled HR ...
or on the link below. The treatment landscape for advanced hepatocellular carcinoma has changed dramatically over the past 4 years. We now have numerous options for patients in frontline, second-line, ...
Blossomhill Therapeutics Inc. has synthesized new indazole-based macrocyclic compounds acting as ALK tyrosine kinase receptor inhibitors potentially useful for the treatment of cancer.
Patients maintain their improvements off treatment, even after clearance of barzolvolimab, investigators report.
Nuvalent Inc. has identified proto-oncogene tyrosine-protein kinase ROS (ROS1; MCF3) and/or ALK tyrosine kinase receptor inhibitors reported to be useful for the treatment of cancer.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system (CNS) disorders, ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Tyrosine kinase inhibitors (TKIs) are emerging as a ...
Multiple sclerosis (MS) is a chronic, immune-mediated, neurodegenerative condition that results in progressive accumulation of disability over the course of the disease. MS presents heterogeneously, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results